Literature DB >> 3042202

HyperapoB: a pleiotropic phenotype characterized by dense low-density lipoproteins and associated with coronary artery disease.

P O Kwiterovich1.   

Abstract

HyperapoB, a lipoprotein phenotype characterized by increased numbers of small, dense, low-density lipoproteins (LDL), is strongly associated with coronary artery disease (CAD). Patients with hyperapoB may be normolipidemic, hypertriglyceridemic, or, when the number of LDL particles increases sufficiently, hypercholesterolemic. Concentrations of high-density lipoprotein (HDL) and its major apolipoprotein, apo A-1, are often low in plasma of patients with hyperapoB. The increased number of dense LDL in hyperapoB is due to increased LDL synthesis, secondary to increased synthesis of very-low-density lipoproteins (VLDL) and apo B. HyperapoB may be a dominant trait, although the existence of a common recessive allele at a very high frequency has not been excluded. The expression of hyperapoB appears delayed, but the phenotype is commonly found in children referred to specialty lipid clinics because of a family history of premature CAD. Published data suggest a biochemical, genetic, and metabolic relationship between hyperapoB, familial combined hyperlipidemia, and the dense LDL subclass patterns described in Mormon families. The biochemical and genetic basis for the overproduction of VLDL apo B is under further study, both molecular investigations of the apo B gene and studies of free fatty acid, triglyceride, and HDL metabolism.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3042202

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  7 in total

1.  Both inherited susceptibility and environmental exposure determine the low-density lipoprotein-subfraction pattern distribution in healthy Dutch families.

Authors:  J de Graaf; D W Swinkels; A F de Haan; P N Demacker; A F Stalenhoef
Journal:  Am J Hum Genet       Date:  1992-12       Impact factor: 11.025

Review 2.  Is it LDL particle size or number that correlates with risk for cardiovascular disease?

Authors:  H Robert Superko; Radhika R Gadesam
Journal:  Curr Atheroscler Rep       Date:  2008-10       Impact factor: 5.113

3.  Apolipoprotein A1 Baltimore (Arg10----Leu), a new ApoA1 variant.

Authors:  J A Ladias; P O Kwiterovich; H H Smith; S K Karathanasis; S E Antonarakis
Journal:  Hum Genet       Date:  1990-04       Impact factor: 4.132

4.  Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance.

Authors:  M Castro Cabezas; T W de Bruin; H W de Valk; C C Shoulders; H Jansen; D Willem Erkelens
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

5.  Effect of glycated LDL on microvascular tone in mice: a comparative study with LDL modified in vitro or isolated from diabetic patients.

Authors:  P Nivoit; N Wiernsperger; P Moulin; M Lagarde; C Renaudin
Journal:  Diabetologia       Date:  2003-10-24       Impact factor: 10.122

6.  Comparison of assessment techniques: plasma lipid and lipoproteins related to the metabolic syndrome.

Authors:  Brenda M Davy; Kevin P Davy
Journal:  Lipids Health Dis       Date:  2006-01-31       Impact factor: 3.876

Review 7.  Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date.

Authors:  Antonio Gaddi; A F G Cicero; F O Odoo; A A Poli; R Paoletti
Journal:  Vasc Health Risk Manag       Date:  2007
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.